Lundberg Laboratory for Cancer Research, Department of Pathology, Sahlgrenska Academy at Göteborg University, Göteborg, Sweden.
BMC Cancer. 2010 Jun 1;10:249. doi: 10.1186/1471-2407-10-249.
The FUS-DDIT3 fusion oncogene encodes an abnormal transcription factor that has a causative role in the development of myxoid/round-cell liposarcomas (MLS/RCLS). We have previously identified FLT1 (VEGFR1) as a candidate downstream target gene of FUS-DDIT3. The aim of this study was to investigate expression of FLT1 and its ligands in MLS cells.
HT1080 human fibrosarcoma cells were transiently transfected with FUS-DDIT3-GFP variant constructs and FLT1 expression was measured by quantitative real-time PCR. In addition, FLT1, PGF, VEGFA and VEGFB expression was measured in MLS/RCLS cell lines, MLS/RCLS tumors and in normal adiopocytes. We analyzed nine cases of MLS/RCLS and one cell line xenografted in mice for FLT1 protein expression using immunohistochemistry. MLS/RCLS cell lines were also analyzed for FLT1 by immunofluorescence and western blot. MLS/RCLS cell lines were additionally treated with FLT1 tyrosine kinase inhibitors and assayed for alterations in proliferation rate.
FLT1 expression was dramatically increased in transfected cells stably expressing FUS-DDIT3 and present at high levels in cell lines derived from MLS. The FLT1 protein showed a strong nuclear expression in cells of MLS tissue as well as in cultured MLS cells, which was confirmed by cellular fractionation. Tissue array analysis showed a nuclear expression of the FLT1 protein also in several other tumor and normal cell types including normal adipocytes. The FLT1 ligand coding gene PGF was highly expressed in cultured MLS cells compared to normal adipocytes while the other ligand genes VEGFA and VEGFB were expressed to lower levels. A more heterogeneous expression pattern of these genes were observed in tumor samples. No changes in proliferation rate of MLS cells were detected at concentrations for which the kinase inhibitors have shown specific inhibition of FLT1.
Our results imply that FLT1 is induced as an indirect downstream effect of FUS-DDIT3 expression in MLS. This could be a consequence of the ability of FUS-DDIT3 to hijack parts of normal adipose tissue development and reprogram primary cells to a liposarcoma-like phenotype. The findings of nuclear FLT1 protein and expression of corresponding ligands in MLS and normal tissues may have implications for tissue homeostasis and tumor development through auto- or intracrine signaling.
FUS-DDIT3 融合癌基因编码一种异常的转录因子,它在黏液样/圆形细胞脂肪肉瘤(MLS/RCLS)的发生发展中起因果作用。我们之前已经确定 FLT1(VEGFR1)是 FUS-DDIT3 的候选下游靶基因。本研究旨在研究 MLS 细胞中 FLT1 及其配体的表达。
瞬时转染 HT1080 人纤维肉瘤细胞 FUS-DDIT3-GFP 变体构建体,并通过实时定量 PCR 测量 FLT1 的表达。此外,还测量了 MLS/RCLS 细胞系、MLS/RCLS 肿瘤和正常脂肪细胞中 FLT1、PGF、VEGFA 和 VEGFB 的表达。我们使用免疫组织化学分析了 9 例 MLS/RCLS 病例和 1 例异种移植在小鼠中的 FLT1 蛋白表达。通过免疫荧光和 Western blot 分析 MLS/RCLS 细胞系中的 FLT1。此外,还对 MLS/RCLS 细胞系进行了 FLT1 酪氨酸激酶抑制剂处理,并检测了增殖率的变化。
稳定表达 FUS-DDIT3 的转染细胞中 FLT1 表达显著增加,并且在源自 MLS 的细胞系中高表达。FLT1 蛋白在 MLS 组织的细胞中表现出强烈的核表达,在培养的 MLS 细胞中也是如此,这通过细胞分离得到证实。组织阵列分析显示,在包括正常脂肪细胞在内的几种其他肿瘤和正常细胞类型中,FLT1 蛋白也表现出核表达。与正常脂肪细胞相比,培养的 MLS 细胞中 FLT1 编码基因 PGF 的表达水平较高,而其他配体基因 VEGFA 和 VEGFB 的表达水平较低。在肿瘤样本中观察到这些基因的表达模式更为多样。在激酶抑制剂显示出对 FLT1 的特异性抑制的浓度下,未检测到 MLS 细胞增殖率的变化。
我们的结果表明,FLT1 是 MLS 中 FUS-DDIT3 表达的间接下游效应诱导的。这可能是 FUS-DDIT3 劫持部分正常脂肪组织发育并将原代细胞重编程为脂肪肉瘤样表型的结果。在 MLS 和正常组织中发现核 FLT1 蛋白和相应配体的表达可能通过自身或内源性信号对组织稳态和肿瘤发展产生影响。